Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.54 |
| ▸ | CCR8 | P51685 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422361 | 0.84 | CCR1 (0.75) | CCR1CCR8CYP2A6ALDH1A1TGFBR1 | |
| SCHEMBL3266995 | 0.82 | IDO1 (0.51) | CCR1CCR8CYP2A6 | |
| SCHEMBL2614970 | 0.78 | CCR1 (0.65) | CCR1CCR8HSD11B1CYP2A6ALDH1A1 | |
| SCHEMBL15522480 | 0.78 | SCN9A (0.46) | GAAHSD11B1SCN9A | |
| SCHEMBL18105512 | 0.78 | ASIC3 (0.60) | GAAHSD11B1SCN9AEGLN2 | |
| SCHEMBL24149351 | 0.77 | CCR1 (0.50) | CCR1GAAHSD11B1CYP2A6ALDH1A1 | |
| SCHEMBL12318156 | 0.77 | CCR1 (0.48) | CCR1CCR8CYP2A6TGFBR1 | |
| SCHEMBL3270284 | 0.77 | GRM5 (0.48) | CCR1CCR8 | |
| SCHEMBL2189142 | 0.76 | KMT2A (0.62) | CCR1CCR8HSD11B1CYP2A6ALDH1A1 | |
| SCHEMBL13681301 | 0.76 | CYP2A6 (0.50) | CCR1CCR8CYP2A6EGLN2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250359476-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | KYULUX INC (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12369492-B2 | Composition of matter for use in organic light-emitting diodes | KYULUX, INC. (JP) | 2025-07-22 | — | — | US | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
| US-8034818-B2 | Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| CN-102174022-A | Synthesis method and application of 1-alkyl-2-substituted phenylbenzimidazole compound | NANJING UNIVERSITY OF TECHNOLOGY | 2011-09-07 | — | — | CN | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CCR1 105/4885CCR8 199/4885GAA 1376/4885 |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | USP30, USP28, USP1 | CCR1 2448/4885CCR8 4163/4885GAA 1770/4885 |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | CCR1 2448/4885CCR8 4163/4885GAA 1770/4885 |
| US-20250359476-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | CRY2, SLCO1B3, NDUFV3 | CCR1 3762/4885CCR8 3793/4885GAA 964/4885 |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | CCR1 2448/4885CCR8 4163/4885GAA 1770/4885 |
| US-12369492-B2 | Composition of matter for use in organic light-emitting diodes | CRY2, SLCO1B3, NDUFV3 | CCR1 3762/4885CCR8 3793/4885GAA 964/4885 |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, H1-2 | CCR1 243/4885CCR8 426/4885GAA 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.